NCT04830800View on ClinicalTrials.gov

A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1)

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

June 6, 2021

Study Completion Date

October 31, 2021

Conditions
COVID-19 DiseaseSARS PneumoniaPneumonia, ViralCOVID-19 Vaccine
Interventions
BIOLOGICAL

COVIVAC

COVIVAC vaccine, manufactured by IVAC with or without adjuvant CpG1018 for prevention of COVID-19

BIOLOGICAL

Phosphate-buffered saline

Phosphate buffer solution (pH 7.2), manufactured by IVAC

Trial Locations (1)

10000

Hanoi Medical University, Hanoi

All Listed Sponsors
collaborator

National Institute of Hygiene and Epidemiology, Vietnam

OTHER

collaborator

Hanoi Medical University

OTHER

lead

Institute of Vaccines and Medical Biologicals, Vietnam

INDUSTRY

NCT04830800 - A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1) | Biotech Hunter | Biotech Hunter